Tauopathy Explained

Tauopathy

Tauopathies are a class of neurodegenerative diseases characterized by the aggregation of abnormal tau protein.[1] Hyperphosphorylation of tau proteins causes them to dissociate from microtubules and form insoluble aggregates called neurofibrillary tangles.[2] Various neuropathologic phenotypes have been described based on the anatomical regions and cell types involved as well as the unique tau isoforms making up these deposits. The designation 'primary tauopathy' is assigned to disorders where the predominant feature is the deposition of tau protein. Alternatively, diseases exhibiting tau pathologies attributed to different and varied underlying causes are termed 'secondary tauopathies'. Some neuropathologic phenotypes involving tau protein are Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.

Tau protein

Tau protein (also called tubulin associated unit or microtubule-associated protein tau (MAPT)) is a microtubule-associated protein that promotes polymerization and stabilization into microtubules by binding to tubulin. Variants of Tau isoforms, spanning from 352 to 441 amino acids, arise through the alternative splicing of exons 2,3 and 10 within the MAPT gene. The six isoforms are differentiated by the inclusion and exclusion of inserts of either 29 or 58 amino acids in the N-terminus domain. Furthermore, the isoforms are categorized based on the presence of either three (3R tau isoforms) or four (4R tau isoforms) tandem repeat sequences each consisting of 31 or 32 amino acids.[3]

Biomarkers

Neuroimaging

Positron emission tomography (PET) is one type of biomarker which is capable of identify patient with elevated levels of tau at patient with Alzheimers disease. PET is a great tool which can supplement information such as various regions having higher neuropathologic burden than others. But it needs to be eligible, and more positive outcome than negative, such as exposure to radioactivity.[4]

Biofluid

The analysis of cerebrospinal fluid (CSF) represents a potential avenue for the development of biomarkers in tauopathies. Substantial data on CSF biomarkers is available for Alzheimer's disease (AD), focusing on measures related to total and phosphorylated forms of tau and amyloid-beta (Aβ) protein. Elevated CSF tau and decreased Aβ levels constitute the characteristic CSF signature of AD, allowing differentiation from controls.[5] This signature may also assist in distinguishing atypical forms of AD pathology associated with clinical frontotemporal dementia (FTD) from those with underlying frontotemporal lobar degeneration (FTLD)-Tau pathology[6]

Alzheimer's disease

Alzheimer's disease (AD) is clinically characterized by a progressive decline in memory and cognitive functions, leading to severe dementia. Microscopically, AD is identified by the presence of two types of insoluble fibrous materials: (1) extracellular amyloid (Aß) protein forming senile plaques and (2) intracellular neurofibrillary lesions (NFL) composed of abnormally and hyperphosphorylated tau protein. While AD is not strictly considered a prototypical tauopathy, as tau pathology coexists with Aß protein deposition, the 'amyloid cascade hypothesis' posits that Aß accumulation is the primary factor driving AD pathogenesis.[7] [8] Nevertheless, AD neurofibrillary lesions were the first to undergo ultrastructural and biochemical analysis, thus laying the foundation for in-depth studies on tau protein deposition in various tauopathies [9]

Neuropathologic phenotypes

Frontotemporal dementia

Frontotemporal dementia is a part of a diverse spectrum of disorders clinically marked by dysfunction in the frontal and temporal lobes, collectively referred to as frontotemporal lobar degeneration (FTLD). The primary histological characteristics include profound neuronal loss, enlarged neurons, and distinctive spherical argyrophilic inclusions known as Pick bodies (PBs). These PBs primarily consist of hyperphosphorylated tau protein, with tau protein presenting as two major bands at 60 and 64 kDa and a variable, minor band at 69 kDa. Filamentous tau deposits in nerve cells are predominantly composed of 3R tau isoforms.[10]

Progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a type of tauopathy, but the cause is not yet discovered. For PSP unusual phosphorylation for tau protein causes vital protein filaments in the nerve cells to destruct, a phenomenon called "neurofibrillary" degeneration. Typical symptoms of PSP would be abnormal speech, balance impairment and overcognitive and memory impairment. As CBD, PSP is also classified as a 4R tauopathy, and because of that PSP will often be selected for trials regarding anti-tau therapeutics.[11] [12]

Corticobasal degeneration

Corticobasal degeneration (CBD) is an increasingly acknowledged neurodegenerative disorder characterized by both motor and cognitive dysfunction. In affected regions, histological examination reveals pronounced neuronal loss accompanied by spongiosis and gliosis, cortical ballooned cells, and notable intracytoplasmic filamentous tau pathology in both glial and neuronal cells. Biochemically, the distinctive tau profile in CBD cases manifests as a prominent tau doublet at 64 and 68 kDa, which is variably identified. These bands predominantly consist of hyperphosphorylated 4R tau isoforms, leading to the classification of CBD as a 4R tauopathy.[13]

Tau therapeutics

Currently, there are no specific treatments for tauopathies. Up till now, attempts have been made to target neurotransmitter disturbances to relieve disease symptoms. For AD a specific treatment is difficult because the pathological changes both early compared to the symptoms showing.[14] Even though there is no current treatment for tauopathies, there are treatments that can relieve symptoms. Speech therapy can be beneficial for aphasia symptoms, symptoms such as depression and apathy frequently engaged with pharmaceuticals. For physical challenges, physical therapy has proven helpful in extending motor function for patients.[15]

Other diseases

See also

Notes and References

  1. Book: Kovacs . Gabor G. . Handbook of Clinical Neurology, volume 145 . Tauopathies . Handbook of Clinical Neurology . 2018 . Gabor G. Kovacs. Irina Alafuzoff. 355–368 . 10.1016/B978-0-12-802395-2.00025-0. 28987182 . 978-0-12-802395-2 .
  2. Goedert M, Spillantini MG . Propagation of Tau aggregates . Molecular Brain . 10 . 1 . 18 . May 2017 . 28558799 . 5450399 . 10.1186/s13041-017-0298-7 . free .
  3. Goedert . M. . Spillantini . M.G. . Jakes . R. . Rutherford . D. . Crowther . R.A. . Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease . Neuron . October 1989 . 3 . 4 . 519–526 . 10.1016/0896-6273(89)90210-9. 2484340 .
  4. Moloney . Christina M. . Labuzan . Sydney A. . Crook . Julia E. . Siddiqui . Habeeba . Castanedes-Casey . Monica . Lachner . Christian . Petersen . Ronald C. . Duara . Ranjan . Graff-Radford . Neill R. . Dickson . Dennis W. . Mielke . Michelle M. . Murray . Melissa E. . Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain . Alzheimer's & Dementia . March 2023 . 19 . 3 . 1029–1040 . 10.1002/alz.12749 . 35920592 . en . 1552-5260. 9895127 .
  5. Shaw . Leslie M. . Vanderstichele . Hugo . Knapik-Czajka . Malgorzata . Clark . Christopher M. . Aisen . Paul S. . Petersen . Ronald C. . Blennow . Kaj . Soares . Holly . Simon . Adam . Lewczuk . Piotr . Dean . Robert . Siemers . Eric . Potter . William . Lee . Virginia M.-Y. . Trojanowski . John Q. . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects . Annals of Neurology . April 2009 . 65 . 4 . 403–413 . 10.1002/ana.21610. 19296504 . 2696350 .
  6. Irwin . David J. . McMillan . Corey T. . Toledo . Jon B. . Arnold . Steven E. . Shaw . Leslie M. . Wang . Li-San . Van Deerlin . Vivianna . Lee . Virginia M.-Y. . Trojanowski . John Q. . Grossman . Murray . Comparison of Cerebrospinal Fluid Levels of Tau and Aβ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms . Archives of Neurology . 1018–1025 . 10.1001/archneurol.2012.26 . 1 August 2012. 69 . 8 . 22490326 . 3528180 .
  7. Hardy . John . Selkoe . Dennis J. . The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics . Science . 19 July 2002 . 297 . 5580 . 353–356 . 10.1126/science.1072994. 12130773 .
  8. Nussbaum . Robert L. . Ellis . Christopher E. . Alzheimer's Disease and Parkinson's Disease . New England Journal of Medicine . 3 April 2003 . 348 . 14 . 1356–1364 . 10.1056/NEJM2003ra020003. 12672864 .
  9. Tolnay . Markus . Probst . Alphonse . The Neuropathological Spectrum of Neurodegenerative Tauopathies . IUBMB Life . June 2003 . 55 . 6 . 299–305 . 10.1080/1521654032000114348. 12938731 .
  10. Tolnay . Markus . Probst . Alphonse . The Neuropathological Spectrum of Neurodegenerative Tauopathies . IUBMB Life . June 2003 . 55 . 6 . 299–305 . 10.1080/1521654032000114348. 12938731 .
  11. Coughlin . David G. . Litvan . Irene . Progressive supranuclear palsy: Advances in diagnosis and management . Parkinsonism & Related Disorders . April 2020 . 73 . 105–116 . 10.1016/j.parkreldis.2020.04.014. 32487421 . 7462164 .
  12. Web site: Progressive Supranuclear Palsy - Symptoms, Causes, Treatment NORD . rarediseases.org.
  13. Tolnay . Markus . Probst . Alphonse . The Neuropathological Spectrum of Neurodegenerative Tauopathies . IUBMB Life . June 2003 . 55 . 6 . 299–305 . 10.1080/1521654032000114348. 12938731 .
  14. Khan . Sahil . Barve . Kalyani H. . Kumar . Maushmi S. . Recent Advancements in Pathogenesis, Diagnostics, and Treatment of Alzheimer's Disease . Current Neuropharmacology . 2020 . 18 . 11 . 1106–1125 . 10.2174/1570159X18666200528142429. 32484110 . 7709159 .
  15. Orr . Miranda E. . Sullivan . A. Campbell . Frost . Bess . A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies . Trends in Pharmacological Sciences . July 2017 . 38 . 7 . 637–648 . 10.1016/j.tips.2017.03.011. 28455089 . 5476494 .
  16. Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF . The MAPT H1 haplotype is associated with tangle-predominant dementia . Acta Neuropathologica . 124 . 5 . 693–704 . November 2012 . 22802095 . 3608475 . 10.1007/s00401-012-1017-1 .
  17. Jellinger KA, Attems J . Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease . Acta Neuropathologica . 113 . 2 . 107–17 . February 2007 . 17089134 . 10.1007/s00401-006-0156-7 . 5655388 .
  18. McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, Perl DP, Stein TD, Vonsattel JP, Stewart W, Tripodis Y, Crary JF, Bieniek KF, Dams-O'Connor K, Alvarez VE, Gordon WA . The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy . Acta Neuropathologica . 131 . 1 . 75–86 . January 2016 . 26667418 . 4698281 . 10.1007/s00401-015-1515-z .
  19. Roberts GW . Immunocytochemistry of neurofibrillary tangles in dementia pugilistica and Alzheimer's disease: evidence for common genesis . Lancet . 2 . 8626–8627 . 1456–8 . 1988 . 2904573 . 10.1016/S0140-6736(88)90934-8 . 32662671 .
  20. Williams DR, Lees AJ . Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges . The Lancet. Neurology . 8 . 3 . 270–9 . March 2009 . 19233037 . 10.1016/S1474-4422(09)70042-0 . 1417930 .
  21. Tolnay . Markus . Probst . Alphonse . The Neuropathological Spectrum of Neurodegenerative Tauopathies . IUBMB Life . June 2003 . 55 . 6 . 299–305 . 10.1080/1521654032000114348. 12938731 .
  22. Selkoe DJ, Podlisny MB . Deciphering the genetic basis of Alzheimer's disease . Annual Review of Genomics and Human Genetics . 3 . 67–99 . 2002 . 12142353 . 10.1146/annurev.genom.3.022502.103022 . free .
  23. Darwich NF, Phan JM, et al. . Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau . Science . 370 . eaay8826 . 2020 . 6519 . 33004675 . 10.1126/science.aay8826. 7818661 .
  24. Hof PR, Nimchinsky EA, Buée-Scherrer V, Buée L, Nasrallah J, Hottinger AF, Purohit DP, Loerzel AJ, Steele JC, Delacourte A . Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders . Acta Neuropathologica . 88 . 5 . 397–404 . 1994 . 7847067 . 10.1007/BF00389490 . 2821768 .
  25. Brat DJ, Gearing M, Goldthwaite PT, Wainer BH, Burger PC . Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype . Neuropathology and Applied Neurobiology . 27 . 3 . 197–205 . June 2001 . 11489139 . 10.1046/j.1365-2990.2001.00311.x . 36482221 .
  26. Halper J, Scheithauer BW, Okazaki H, Laws ER . Meningio-angiomatosis: a report of six cases with special reference to the occurrence of neurofibrillary tangles . Journal of Neuropathology and Experimental Neurology . 45 . 4 . 426–46 . July 1986 . 3088216 . 10.1097/00005072-198607000-00005 . 663552 .
  27. Paula-Barbosa MM, Brito R, Silva CA, Faria R, Cruz C . Neurofibrillary changes in the cerebral cortex of a patient with subacute sclerosing panencephalitis (SSPE) . Acta Neuropathologica . 48 . 2 . 157–60 . November 1979 . 506699 . 10.1007/BF00691159 . 36105401 .
  28. Wisniewski K, Jervis GA, Moretz RC, Wisniewski HM . Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia . Annals of Neurology . 5 . 3 . 288–94 . March 1979 . 156000 . 10.1002/ana.410050311 . 25649751 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tauopathy".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.